Component

Human Alzheimer trial cognitive and functional decline

Human Alzheimer trial cognitive and functional decline

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. The prospective early-onset Alzheimer trial also found no primary intention-to-treat benefit of ALCAR.

    Acetyl-L-carnitine → Human Alzheimer trial cognitive and functional decline Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    experimental_contrast
    {"intervention": "ALCAR 3 g/day for one year", "comparator": "Placebo", "endpoint": "The prospective early-onset Alzheimer trial also found no primary intention-to-treat benefit of ALCAR.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    229 randomized, ages 45–65; ALCAR 1 g three times daily versus placebo for one year.
    interpretation_status
    Source-derived curation with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
    plain_language
    The prospective early-onset Alzheimer trial also found no primary intention-to-treat benefit of ALCAR.
    primary_references
    A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. | https://pubmed.ncbi.nlm.nih.gov/10994000/ | https://doi.org/10.1212/wnl.55.6.805
    source_locator
    Reviewed reference ad00-null; A completer-only MMSE signal did not overturn null primary ADAS-cognitive and CDR results.

    Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 603–609

    AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · 229 randomized, ages 45–65; ALCAR 1 g three times daily versus placebo for one year. · Recorded from source · Recorded from source

    ### ad00-null The prospective early-onset Alzheimer trial also found no primary intention-to-treat benefit of ALCAR. A completer-only MMSE signal did not overturn null primary ADAS-cognitive and CDR results. Model and exposure: 229 randomized, ages 45–65; ALCAR 1 g three times daily versus placebo for one year. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. | 2000 | https://pubmed.ncbi.nlm.nih.gov/10994000/ | https://doi.org/10.1212/wnl.55.6.805 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    Complete structured claim and evidence

  2. ALCAR did not slow overall primary cognitive/clinical decline in the 431-participant Alzheimer trial.

    Acetyl-L-carnitine → Human Alzheimer trial cognitive and functional decline Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    experimental_contrast
    {"intervention": "ALCAR 3 g/day for one year", "comparator": "Placebo", "endpoint": "ALCAR did not slow overall primary cognitive/clinical decline in the 431-participant Alzheimer trial.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Mild-to-moderate probable AD; 3 g/day versus placebo, 12 months, 1996.
    interpretation_status
    Source-derived curation with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
    plain_language
    ALCAR did not slow overall primary cognitive/clinical decline in the 431-participant Alzheimer trial.
    primary_references
    A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. | https://pubmed.ncbi.nlm.nih.gov/8797468/ | https://doi.org/10.1212/wnl.47.3.705
    source_locator
    Reviewed reference ad96-null; Post hoc age-subgroup trends were exploratory and motivated prospective testing.

    Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 595–601

    AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · Mild-to-moderate probable AD; 3 g/day versus placebo, 12 months, 1996. · Recorded from source · Recorded from source

    ### ad96-null ALCAR did not slow overall primary cognitive/clinical decline in the 431-participant Alzheimer trial. Post hoc age-subgroup trends were exploratory and motivated prospective testing. Model and exposure: Mild-to-moderate probable AD; 3 g/day versus placebo, 12 months, 1996. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. | 1996 | https://pubmed.ncbi.nlm.nih.gov/8797468/ | https://doi.org/10.1212/wnl.47.3.705 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.